Method Transfer and Full Method Validation, Partial Validation in cGMP Environment

Authors: Sai Raghuveer Chava*, Jingbo Liu and Sajid Bashir

DOI: 10.23880/aabsc-16000143

Volume 2, Issue 2

Abstract

This paper describes the current method transfer and method validation process following FDA guidance and ICH guidelines in a cGMP environment. The analytical method validation and transfer have been playing a key role in Phase 1 to Phase 3 projects. This paper discusses the method validation and method transfer based on the phase of relevance in the GMP environment. It also describes the number of validation or qualification steps required for the method transfer. When the analytical methods are utilized to generate results about the characteristics of drug-related samples it is essential that the results are trustworthy. They may be utilized as the basis for decisions relating to administering the drug to patients. Analytical method validation required during drug development and manufacturing and these analytical methods is fit for their intended purpose. To comply with the requirements of GMP pharmaceutical industries should have an overall validation policy that documents how validation will be performed. The purpose of this validation is to show that processes involved in the development and manufacture of the drug, production, and analytical testing can be performed in an effective and reproducible manner. This review article provides guidance on how to perform validation characteristics for the analytical method which are utilized in pharmaceutical analysis.

Keywords: Validation Methods; Analytical Methodology; cGMP; ICH Guidelines

View PDF